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Abstract
PTPN11 encodes the Shp2 non-receptor protein-tyrosine phosphatase implicated in several 
signaling pathways. Activating mutations in Shp2 are commonly associated with juvenile 
myelomonocytic leukemia (JMML) but are not as well defined in other neoplasms. Here we report 
that Shp2 mutations occur in human acute myeloid leukemia (AML) at a rate of 6.6% (6/91) in the 
ECOG E1900 dataset. We examined the role of mutated Shp2 in leukemias harboring MLL 
translocations which co-occur in human AML. The hyperactive Shp2E76K mutant, commonly 
observed in leukemia patients, significantly accelerated MLL-AF9 mediated leukemogenesis in 
vivo. Shp2E76K increased leukemic stem cell frequency and affords MLL-AF9 leukemic cells IL3 
cytokine hypersensitivity. As Shp2 is reported to regulate anti-apoptotic genes, we investigated 
Bcl2, Bcl-xL and Mcl1 expression in MLL-AF9 leukemic cells with and without Shp2E76K. 
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While the Bcl2 family of genes was upregulated in Shp2E76K cells, Mcl1 showed the highest 
upregulation in MLL-AF9 cells in response to Shp2E76K. Indeed, expression of Mcl1 in MLL-
AF9 cells phenocopies expression of Shp2E76K suggesting Shp2 mutations cooperate through 
activation of anti-apoptotic genes. Finally, we show Shp2E76K mutations reduce sensitivity of 
AML cells to small molecule mediated Mcl1 inhibition suggesting reduced efficacy of drugs 
targeting MCL1 in patients with hyperactive Shp2.
Introduction
MLL rearrangements are present in ~20% of pediatric AML and can be as high as 80% of 
infant patients with ALL (1) and are generally associated with a poor outcome (2). 
Rearrangements of the MLL locus generate potent oncogenic fusion proteins that retain the 
N-terminus of the MLL protein but replace the C-terminus with one of >60 different partner 
proteins that can recruit transcriptional activation complexes (3–6). The resultant 
deregulated transcriptional activation mediated by MLL fusion proteins blocks 
hematopoietic differentiation through the sustained expression of the posterior HOXA gene 
cluster, namely HOXA9 (7). Interestingly, MLL leukemias display a relatively stable 
genome compared with other leukemic subtypes but still carry other genetic lesions at low 
frequency (8). Type-I mutations involving the Ras pathway are present in about 37% of 
MLL rearranged leukemias including mutations within NRAS, KRAS, NF1 and PTPN11 (9), 
consistent with the idea that pathological AML requires both type-I and type-II mutations 
(10). Indeed, oncogenic NRASG12V or FLT3-ITD can significantly accelerate MLL fusion 
protein mediated leukemogenesis in vivo (11–13). Although these mutations strongly 
cooperate with MLL fusion proteins to promote leukemogenesis, little is understood about 
the molecular mechanisms utilized by type-I mutations.
PTPN11 encodes the ubiquitously expressed SHP2 non-receptor protein tyrosine 
phosphatase involved in the RAS, JAK-STAT, PI3K and other pathways (14, 15). Mutations 
in PTPN11 are found in ~50% of patients with Noonan syndrome, as well as, ~37% of 
patients with hematologic malignancies such as juvenile myelomonocytic leukemia 
(JMML), ALL and AML (16–19). Recent genome-wide sequencing analyses have identified 
PTPN11 mutations in AML patients indicating this may function in a cooperative manner 
(20, 21). Shp2 positively regulates signal transduction pathways downstream of receptor 
tyrosine kinases, like Kit, where it is essential for hematopoietic stem and progenitor cells 
(22, 23). Hematopoietic progenitors require Shp2 for STAT5 activation and upregulation of 
Mcl1 and Bcl-xL (24, 25). In leukemia expression is often elevated and Shp2 can associate 
with FLT3-ITD leading to activation of STAT5. Shp2 co-localizes with STAT5 to activate 
expression of Bcl-xL protecting against cell death (26, 27). PTPN11 mutations result in 
amino acid changes resulting in disrupted autoinhibition and hyperactive Shp2 enzymatic 
activity (17, 28–30). Gain of function mutations in Shp2 result in cytokine hypersensitivity 
in hematopoietic progenitor cells (31). In mice, gain of function Shp2 mutations leads to a 
JMML-like fatal myeloproliferative disease whereas an inducible mutant Shp2 knock-in 
mouse model progresses to AML, as well as, B and T cell ALL with long disease latency 
(32–35). However, the molecular mechanisms leading to disease and the cooperative nature 
of hyperactive Shp2 with leukemic fusion proteins has not been explored.
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To investigate whether mutations associated with PTPN11 can cooperate with oncogenic 
fusion proteins, we developed a mouse model of cooperative leukemogenesis with MLL-
AF9 and the leukemia-associated Shp2E76K mutant that shows the highest basal 
phosphatase activity among all the disease-associated Shp2 mutations (17, 36). Shp2E76K 
strongly cooperates with MLL-AF9 to accelerate leukemogenesis in mice by altering 
leukemic stem cell frequency. MLL-AF9 Shp2E76K cells display cytokine hypersensitivity 
and activation of the Erk pathway leading to upregulation of an anti-apoptotic gene program 
most prominently observed with Mcl1. We find that Shp2E76K expression in both mouse 
and human cells reduces MLL-AF9 sensitivity to chemical inhibition of Mcl1 suggesting 
mutant Shp2 cooperates mechanistically with MLL fusion proteins through Mcl1 
expression.
Materials and Methods
Mice
Female C57BL/6 mice at 8 to 10 weeks old were purchased from Taconic Farms. B6.Cg-
Gt(ROSA)26Sortm1(rtTA*M2)Jae/J mice (TetOn mice) were purchased from Jackson 
laboratory. All animal studies were approved by the University of Michigan Committee on 
Use and Care of Animals and Unit for Laboratory Medicine.
Genetic analysis of primary patient AML samples
All primary patient samples came from pretreatment AML blood or bone marrow samples 
from patients treated on the ECOG E1900 clinical trial as previously described (37). All 
patient samples were previously evaluated for cytogenetic abnormalities and sequenced for 
the following genes recurrently mutated in AML: ASXL1, CEBPα, CKIT, DNMT3A, EZH2, 
FLT3, NPM1, HRAS, IDH1, IDH2, KRAS, NRAS, PHF6, WT1, RUNX1, TET2, and TP53 
(37). For sequencing of PTPN11, all coding regions of PTPN11 were amplified using 
RainDance microdroplet digital PCR enrichment (RainDance, Billerica, MA) as previously 
described (38, 39) followed by followed by Illumina HiSeq massively parallel sequencing. 
Primer sequences are available upon request.
Plasmids
MSCVpuro-Flag-mMcl1 plasmid was purchased from Addgene (32982). MSCVneo-Flag-
MLL-AF9 and MSCVneo-E2A-HLF plasmids have been described before (40). MIEG3 
(retroviral vector utilizing the bi-cistronic MSCV backbone and expressing enhanced GFP) 
and MIEG3-Shp2E76K plasmids were provided by Dr. Rebecca Chan (Indiana University) 
(41). shRNA plasmids were generated by inserting validated shRNA sequences into the 
XhoI and EcoRI sites of the pTRMPV-Hygro vector (42). Mcl1 shRNAs and Renilla control 
shRNA sequences were described previously (43). All shRNA sequences were listed in 
Supplementary Table 1.
shRNA knockdown
Hematopoietic stem cells purified from TetOn mice were transformed with MLL-AF9 
retrovirus. Freshly transformed (~2 weeks after transduction) cells were transduced with 
MIEG3 or MIEG3-Shp2E76K and sorted by GFP expression. GFP+ cells were transduced 
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with Plat-E packaged shRNA retroviruses. Cells were selected with hygromycin for 1 week 
(140ug/ml for 5 days and 200μg/ml for 2 days) with fresh antibiotics added every 1 to 2 
days. ShRNA containing cells were mixed with shRNA-none cells (i.e. TetOn 
MA9+MIEG3 or TetOn MA9+E76K) at 3:1 ratio and cultured in media containing 1μg/ml 
Doxcycline. 1 day after Doxcycline treatment, cells were harvested for flow cytometry to 
detect dsRed+ cell percentage in the mixed population. ShRNA knockdown after 
doxycycline treatment were verified by western blotting.
Chemical inhibition assay
All chemical inhibitors were dissolved in DMSO. Cells were cultured at 5×104 cells/ml in 
12-well non-tissue culture plate in the presence of serially diluted Inhibitors. ABT-263 was 
added at 0.1, 0.33, 1, 2.5, 5μM. UMI-205, UMI-77, UMI-208, and UMI-212 were added at 
1.25, 2.5, 5, 10, 20μM. DMSO was used as negative control. Cells were enumerated after 48 
hours of culture and the growth rate k was calculated according to the exponential growth 
equation:
Additional methods can be found in Supplemental materials
Results
PTPN11 mutations functionally cooperate with specific oncogenes in AML
To gain insight into the mutational frequency of SHP2 in human AML, we sequenced 
PTPN11 by next-generation sequencing in 91 AML patients enrolled in the phase III clinical 
trial run by ECOG E1900 (47). Six of 91 patients were identified to contain a mutation in 
PTPN11 resulting in a 6.6% mutational frequency in AML; consistent with a saturation 
analysis of cancer genes in AML (20) suggesting PTPN11 mutations are functionally 
important to leukemic transformation (Table 1). All mutations were detected within exon 3 
and resulted in amino acid changes previously associated with both AML and JMML (15, 
17). The E76K, T31I, E76Q, D61Y, F71L and E76G mutations all reside within an auto-
inhibitory region of the SHP2 protein and disrupts the N-SH2 interaction with the PTP 
domain leading to hyperactive phosphatase activity (16, 28). PTPN11 mutations were found 
to co-occur with genetic alterations in DNMT3a, NPM1, WT1, CBF and MLL suggesting 
mutant SHP2 may cooperate functionally in AML. As PTPN11 mutations were previously 
reported in MLL associated leukemias (19), we tested whether hyperactive Shp2 can 
functionally cooperate with MLL fusion proteins in transformation. We performed primary 
bone marrow transduction and colony replating assays using retroviral vectors containing 
the oncogenic MSCV-MLL-AF9 (MA9) fusion protein and the hyperactive Shp2 mutant 
MIEG3-Shp2E76K (E76K) commonly associated with hematologic malignancies. While 
expression of E76K alone did not lead to significant replating potential indicative of cellular 
transformation, the E76K mutant significantly augmented MLL-AF9 mediated colony 
formation as evidenced by a two-fold increase in colony formation in the second round 
compared to MLL-AF9 and empty MIEG3 (Figure 1A and B). Colony formation between 
MA9 and MA9+E76K was similar in tertiary plating that may reflect more efficient 
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transformation or limitations in quantifying CFU potential in the absence of limiting 
dilutions. MA9 and MA9+E76K colonies were dense and composed of immature blast-like 
cells with a greater nuclear to cytoplasmic ratio compared to the diffuse colonies composed 
of macrophage type cells resulting from transduction with empty vectors or E76K alone 
(Figure 1B). Notably, while MLL-AF9 colonies were composed almost exclusively of 
primitive blast-like cells, MLL-AF9 and E76K co-transduced cells consistently contained 
sporadic differentiating macrophages (Figure 1B). To examine cooperation in other 
leukemic subtypes, we tested E76K expression in the presence of the unrelated leukemic 
oncoprotein E2A-HLF (EH) that transforms cells through an anti-apoptotic gene program, 
which is distinct from the HOX gene program used by MLL fusion proteins (48). 
Interestingly, we did not observe a difference in E2A-HLF mediated colony replating 
capacity in the presence of E76K (Figure 1A and B). Expression of Shp2E76K was 
confirmed by qPCR using Shp2 specific primer sets and RNA isolated after the first round 
of the colony assay (Figure 1C). Together, these data identify PTPN11 mutations as co-
occurring with several common hematologic genetic alterations and functionally cooperating 
with MLL-AF9 mediated transformation in vitro.
Hyperactive Shp2 accelerates MLL-AF9 leukemia and alters leukemic stem cell frequency
We next assessed how Shp2 mutations affected MA9 mediated leukemogenesis in vivo. 
Here we introduced either empty vectors, MSCV+E76K, MA9+MIEG3 or MA9+E76K into 
lin−c-kit+ bone marrow cells by retroviral transduction. Cells were i.v. injected into lethally 
irradiated syngeneic recipients and allowed to engraft. Mice receiving cells transduced with 
empty vectors or MSCV+E76K did not show signs of disease through 150 days suggesting 
overexpression of E76K alone failed to induce a lethal leukemia (Figure 2A). On the 
contrary, overexpression of E76K significantly accelerated MA9 mediated leukemogenesis 
resulting in decreased disease latency (p=0.0004, Log-Rank). The median survival of mice 
receiving MA9+MIEG3 cells (125 days) was more than double the median survival of mice 
receiving MA9+E76K (60 days) (Figure 2A). Mice were monitored for 150 days with the 
first moribund MA9+E76K mouse euthanized on day 38 and the first MA9+MIEG3 mouse 
euthanized on day 103. MA9+MIEG3 or MA9+E76K mice displayed splenomegaly (Figure 
2B) and compromised organ structure in the spleen and liver (Figure 2C). Histopathology 
revealed infiltrating leukemic blasts in the spleen and liver while bone marrow aspirates 
revealed blocked myeloid differentiation in diseased MA9 and MA9+E76K mice (Figure 
2C). Overexpression of Shp2E76K was confirmed by western blotting splenocytes from 
MA9 and MA9+E76K diseased mice (Figure 2D). It is noteworthy that MA9+E76K mice 
with longer disease latencies also showed the lowest expression of Shp2 by western blot 
(Figure 2D). A correlation between Shp2E76K expression level and disease latency was 
established by plotting β-Actin normalized Shp2 protein expression levels against disease 
latency (R2 = 0.90367) (Figure 2D). Overexpression of Ptpn11 was also confirmed by qPCR 
using cDNA from diseased splenocytes (Figure 2E). Remarkably, we did not detect a 
difference in the expression of the direct MLL-AF9 target genes Hoxa9 and Meis1 
suggesting the difference in disease latency is not due to a change in the MLL-AF9 gene 
program induced by Shp2E76K (Figure 2E). To follow up on the difference in cell 
morphology observed in colony assays with MA9 or MA9+E76K (Figure 1B), we 
performed flow cytometry on splenocytes. Cell surface expression of Sca1 and c-kit was 
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similar in both MA9 and MA9+E76K cells (Figure 2F). However, expression of both Cd11b 
and Gr1 were significantly higher in MA9+E76K cells compared to MA9 cells, consistent 
with a slightly more differentiated phenotype (Figure 2F). These data are consistent with a 
role of Shp2 in promoting hematopoietic differentiation through dephosphorylation of 
Runx1 (49). To understand if accelerated leukemogenesis in the presence of E76K was due 
to altered leukemic stem cell (LSC) frequency, we performed a limiting dilution assay with 
primary leukemic cells isolated from MA9 and MA9+E76K diseased mice. These were 
injected into secondary recipients following sublethal irradiation and monitored for 109 days 
for disease. While MA9 cells displayed an LSC frequency of ~1 in 285, the presence of 
E76K significantly increased LSC frequency to ~1 in 50 (Figure 2G). These data suggest 
Shp2E76K cooperates with the MLL-AF9 fusion protein in vivo to accelerate 
leukemogenesis by altering LSC frequency.
Shp2E76K affords MLL-AF9 cells cytokine hypersensitivity
To investigate the mechanism of accelerated leukemogenesis, we generated cell lines with 
MA9 or MA9+E76K by retroviral transduction of lin− c-kit+ bone marrow cells. We 
enriched for cells transduced with empty MIEG3 or E76K by sorting for GFP, which 
revealed an expansion of bone marrow cells expressing E76K that was evident four days 
after transduction (Supplementary Figure 1). Proliferation assays demonstrated the E76K 
mediated bone marrow expansion was transient except in the presence of MLL-AF9 which 
initiated leukemic transformation (Figure 3A). Overexpression of mutant Shp2 was 
confirmed by western blot (Figure 3B). Previous studies had implicated hyperactive Shp2 in 
hematopoietic progenitor cell cytokine hypersensitivity (31, 41). We tested this in the 
context of MLL-AF9 leukemic cells by performing an IL3 withdrawal and proliferation 
assay. We observed increased tolerance for IL3 withdrawal in MA9+E76K cells compared 
to MA9 (Figure 3C). This was also accompanied by increased Erk phosphorylation in the 
absence of IL3. MA9+E76K cells displayed higher resting levels of Erk phosphorylation 
with limiting amounts of IL3 and showed greater Erk phosphorylation in response to IL3 
compared to MA9 cells (Figure 3D).
Several studies have linked Shp2 activity with the upregulation of anti-apoptotic genes (24, 
27). Thus, we examined expression of both the Bcl2 family of genes and direct MLL fusion 
targets by qPCR in MA9 and MA9+E76K cells to reveal the mechanism for Shp2E76K 
mediated accelerated leukemogenesis and cytokine hypersensitivity. We found the 
expression of Hoxa9 and Meis1 not significantly changed in the presence of Shp2E76K 
suggesting modulation of MLL targets genes is not responsible for cytokine hypersensitivity 
(Figure 4A). In contrast, we observed a significant upregulation of Bcl-xL and Mcl1 in 
MA9+E76K cells compared to MA9 cells in the presence of low dose IL3 (0.001ng/ml) 
(Figure 4A). The most significant increase was observed in Mcl1 mRNA expression with a 
~4 fold upregulation, which was confirmed by western blot (Figure 4B). This is consistent 
with genetic analyses that identified Mcl1 as a key regulator of cell survival in MLL-ENL 
leukemic cells compared to Bcl2 or Bcl-xL (43). Interestingly, there were only minor 
changes in Hoxa9, Mcl1, Bcl2 or Bcl-xL expression when Shp2E76K was over-expressed in 
normal lin− bone marrow suggesting a context dependent function for hyperactive Shp2 
(Supplemental Figure 2). While all anti-apoptotic genes were upregulated in the presence of 
Chen et al. Page 6
Leukemia. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Shp2E76K, Mcl1 clearly emerged as the most highly expressed and upregulated in 
MA9+E76K cells (Figure 4A). These data suggest that the Shp2E76K mutation may 
accelerate leukemogenesis through the upregulation of an anti-apoptotic gene program 
primarily mediated by Mcl1.
Mcl1 expression recapitulates Shp2E76K mediated cellular effects
Because Mcl1 expression was notably higher than Bcl2 and Bcl-xL, we asked whether 
expression of Mcl1 alone would recapitulate the effects seen by Shp2E76K in MLL-AF9 
cells. To this end, we used an MSCV-puro based Mcl1 retroviral vector for co-transduction 
of lin− c-kit+ bone marrow cells along with MSCV-neo-MLL-AF9 and subsequent colony 
forming and replating assays. Similar to what was seen with co-transduction with 
Shp2E76K, a significant increase in colony formation was observed in the second round of 
the colony assay following co-transduction of MA9 and Mcl1 compared to MA9 and empty 
vector and was evident by visual inspection of the plates (Figure 5A). Transduction with 
Mcl1 alone resulted in a similar number of colonies as empty vector transduced cells and did 
not lead to replating capacity in the second and third round suggesting Mcl1 overexpression 
alone is insufficient for transformation (Figure 5A). Stable cell lines were established from 
lin− c-kit+ bone marrow cells following transduction with MA9+MSCVpuro or MA9+Mcl1. 
To test the effect of Mcl1 expression on cytokine hypersensitivity, we tested proliferation 
rates in serially diluted concentrations of IL3. Overexpression of Mcl1 resulted in a marked 
proliferative advantage in lower doses of IL3 (Figure 5B). We next examined how Mcl1 
expression affected colony forming unit (CFU) frequency by performing a limiting dilution 
colony assay with MA9 and MA9+Mcl1. Strikingly, we observed a significantly higher 
frequency of CFUs per cell plated in MA9+Mcl1 (1/13.32) compared to MA9 alone 
(1/79.11) (Figure 5C). Over-expression of Mcl1 was confirmed by western in Figure 5D. 
Together, these data show expression of Mcl1 results in increased colony formation, 
cytokine hypersensitivity and increased CFU frequency suggesting the cellular effects 
mediated by Shp2E76K may be mediated by expression of Mcl1.
AML cells with PTPN11 mutations are desensitized to Mcl1 inhibition
To further examine the role of anti-apoptotic proteins in MA9+E76K cells, we treated 
established mouse cell lines with chemical inhibitors with specificity towards different anti-
apoptotic proteins. Here, the growth rate of MA9+MIEG3, MA9+E76K, MA9+Mcl1 and 
E2A-HLF cells was assessed following treatment with varying concentrations of ABT-263, 
UMI-212 or UMI-205. ABT-263 is a cell permeable BH3 mimetic chemical inhibitor that 
disrupts Bcl2 and Bcl-xL interactions with pro-death proteins like Bim (50). UMI-212 is a 
novel cell permeable chemical inhibitor that specifically targets Mcl1, without affecting 
Bcl2 or Bcl-xL, and UMI-205 is a control non-targeting compound (51, 52). As expected, no 
change in cell growth was observed in any cell lines following treatment of cells with 
UMI-205 (Figure 6A). In contrast, treatment of cells with ABT-263 resulted in decreased 
growth of E2A-HLF cells without affecting the growth of MA9+MIEG3, MA9+E76K or 
MA9+Mcl1 cells (Figure 6A). E2A-HLF cells showed an IC50 value of 1.80μM compared to 
>5μM for MA9+MIEG3, MA9+E76K and MA9+Mcl1 (Supplementary Table 3). These data 
suggest MLL fusion protein transformed cells are less sensitive to Bcl2 inhibition compared 
to E2A-HLF cells and are consistent with previous work implicating Bcl2 in E2A-HLF 
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mediated leukemic transformation (48). On the contrary, MA9 cells were more sensitive to 
UMI-212 mediated Mcl1 inhibition compared to E2A-HLF cells (Figure 6A). The 
sensitivity of MA9 cells to UMI-212 was reduced with the addition of E76K such that the 
growth pattern was similar to E2A-HLF cells. These data are consistent with decreased 
cellular sensitivity to UMI-212 due to the upregulation of an anti-apoptotic program, most 
notably Mcl1, by E76K. In addition, direct overexpression of Mcl1 in MA9+Mcl1 cells led 
to less sensitivity to UMI-212 similar to expression of E76K (Figure 6A, Supplementary 
Table 3). MA9 cells have an IC50 of 5.197μM compared to 8.389μM, 8.711μM and 
10.76μM for E2A-HLF, MA9+E76K and MA9+Mcl1 cells respectively (Supplementary 
Table 3). Treatment with two additional chemical inhibitors with Mcl1 specificity, MI-77 
and MI-228, yielded comparable results (Supplementary Figure 3). To test if inhibition of 
Mcl1 led to programmed cell death, we examined cell viability by annexin V and DAPI 
staining following treatment with control UMI-205, ABT-263 or UMI-212. While UMI-205 
did not affect cell viability, treatment with UMI-212 led to an increase in annexin V 
positivity indicative of programmed cell death (Figure 6B, and Supplementary Figure 4). 
While not statistically significant in MA9+E76K cells, a trend of decreased annexin V 
positivity was observed in MA9+E76K and MA9+Mcl1 cells compared to MA9 cells 
consistent with the above growth curves and Mcl1 expression, suggesting leukemic cells 
with Shp2 mutations are less responsive to UMI-212 mediated Mcl1 inhibition (Figure 6A 
and B, Supplementary Figure 3, and 4). These data implicate Mcl1 as a crucial mediator of 
MLL-AF9 cell proliferation that is significantly modulated by Shp2E76K rendering 
leukemic cells less sensitive to Mcl1 inhibition.
To verify the desensitization of MA9+E76K cells to UMI-212 was mediated by Mcl1 
overexpression, we engineered inducible pTRMPV retroviral vectors to express validated 
shRNA targeting Mcl1 or control Renilla (Ren) to allow for gene specific knockdown in 
leukemic cells. Freshly established TetOn MA9+MIEG3 and MA9+E76K cell lines were 
infected with the shRNA retroviruses and selected for 1 week. ShRNA containing cells were 
then mixed with parental cell lines lacking either pTRMPV vector at a 3:1 ratio and cultured 
with Doxycycline to induce shRNAs detectable by dsRed expression and flow cytometry. 
Consistent with previous data implicating Mcl1 gene expression in the survival of MLL 
leukemic cells (43), knockdown of Mcl1 with two separate shRNA vectors in MA9 cells led 
to a significantly reduced dsRed+ population in comparison to Ren controls (Figure 6C). 
Similarly, knockdown of Mcl1 in MA9+E76K cells lead to reduced dsRed+ population 
(Figure 6C). Knockdown of Mcl1 was confirmed by western 24 hours after Doxycycline 
treatment (Figure 6D).
We next tested how a variety of human AML cells respond to Mcl1 inhibition. To this end, 
we sequenced several human AML cell lines to determine the mutational status of exon 3 of 
PTPN11. Among the cell lines tested, only U937 cells contained a PTPN11 mutation 
(G60R) (Supplemental Figure 5). To determine how human leukemia cells containing a 
PTPN11 mutation would respond to anti-apoptotic protein inhibition, we treated the 
PTPN11 mutant U937 cell line and the PTPN11 wild type cell lines K562, Monomac6, 
THP-1 and ML2 with ABT-263, UMI-212 or UMI-205. While none of the cell lines showed 
a change in growth response to the control UMI-205 compound, U937 and THP1 cells were 
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clearly more resistant to UMI-212 mediated Mcl1 inhibition compared to K562, MonoMac6 
and ML2 cells (Figure 7A). U937 cells had an IC50 of 17.92μM compared to IC50 values of 
9.72μM and 7.39μM for K562 and ML2 cells and 10.84μM and 15.63μM for MonoMac6 
and THP1 cells (Supplementary Table 3). ML2 and THP1 cells showed slight sensitivity to 
ABT-263 mediated Bcl2/Bcl-xL inhibition (Figure 7A). These results were confirmed with 
additional Mcl1 specific inhibitors, which confirmed U937 desensitization to Mcl1 
inhibition (Supplementary Figure 6). While MCL1 expression varied between cell lines, 
colony forming ability generally decreased in a dose dependent fashion with MCL1 
inhibition (Supplementary Figure 7A, B). U937, K562 and THP1 cells displayed greater 
resistance to MCL1 inhibition compared to ML2 and MonoMac6 cells (Supplementary 
Figure 7A). The increased resistance of THP1 and K562 cells along with U937 cells in 
proliferation and colony assays likely reflect the utility of multiple transformation 
mechanisms that may compensate for loss of MCL1. Of note, THP1 cells harbor activating 
mutations in NRAS that may contribute to increased MCL1 expression. Despite these cell 
lines carrying a variety of driver mutations, including CALM-AF10, BCR-ABL, MLL-AF9 
and MLL-AF6, these data suggest that a Shp2 mutation in human AML cells may result in 
greater resistance to MCL1 inhibition.
Discussion
Cooperative leukemia
Recent deep sequencing efforts have revealed a number of mutations that together with 
previously identified chromosomal abnormalities give a clearer picture of the genetic 
landscape of acute leukemias. The data presented currently provides an experimental 
validation of the premise proposed by Gilliland and others that complete leukemogenesis 
require mutations conferring a block in differentiation and promoting cell survival (10). 
Although mouse models of both MLL-AF9 and Shp2E76K result in lethal leukemias (35, 
53, 54), the long latencies of these diseases suggest cooperating events contribute to the 
disease. The presence of an MLL fusion protein, like MLL-AF9, leads to a block in 
hematopoietic differentiation through the sustained expression of Hoxa9 and Meis1. The 
addition of PTPN11 gain of function mutations lead to functional cooperation between the 
MLL-AF9 fusion protein and mutated Shp2 that results in significantly accelerated 
leukemogenesis by increasing LSC frequency through upregulation of an anti-apoptotic 
gene program that primarily includes Mcl1 (Figure 7B). Upregulation of the Bcl2 family, 
namely Mcl1, induced by activating mutations in Shp2, leads to decreased sensitivity of both 
murine and human leukemia cell lines to Mcl1 inhibitors, suggesting that patients harboring 
PTPN11 mutations (or others within the Ras pathway) may show a poorer response to Mcl1 
inhibition than patients without. Our data also suggest that the signaling pathways linking 
Shp2E76K and Mcl1 overexpression may represent candidates for therapeutic targeting in 
combination with Mcl1 inhibitors.
Mcl1 is associated with transformation and modulated by cooperating mutations
Elegant genetic studies have clearly demonstrated the importance of an anti-apoptotic gene 
program in AML cells using both overexpression and gene depletion techniques. For 
example, transgenic mice over-expressing Mcl1 in hematopoietic cells leads to increased 
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survival in several hematopoietic lineages and immortalization of myeloid cells in the 
presence of IL3 ex vivo (55). Further, mice expressing a modified allele of Mcl1 that 
encodes an abnormally stabilized form of Mcl1 showed accelerated AML induced by 
overexpression of c-MYC (56). These studies are important since MCL1 was shown to be 
the predominant Bcl2 family member overexpressed in AML patient samples. Using 
conditional knock out alleles, Glaser et. al. demonstrated the importance of Mcl1, Bcl2 and 
Bcl-xL in AML cell survival (43). Interestingly, it was shown that MLL fusion protein 
mediated leukemogenesis was most severely inhibited by deletion of Mcl1. However, AML 
cell death following loss of Mcl1 can be compensated for by expression of Bcl2. Further, 
cell death induced by loss of Mcl1 is augmented by treatment with ABT-737 suggesting 
non-overlapping and cooperative roles for Mcl1 and Bcl2 or Bcl-xL in AML cell survival 
(43). Together, these data are consistent with our gene expression analysis showing Mcl1 as 
the most highly expressed of the anti-apoptotic genes in MLL-AF9+Shp2E76K cells (Figure 
4). Further, we observed differential sensitivity between MLL-AF9 and E2A-HLF AML 
cells following treatment with the Bcl2/Bcl-xL inhibitor ABT-263 and a Mcl1 inhibitor 
(Figure 6). E2A-HLF cells showed more sensitivity to Bcl2 inhibition compared to MLL-
AF9 cells, however, MLL-AF9 cells are more sensitive to Mcl1 inhibition compared to 
E2A-HLF cells. This is consistent with the finding that E2A-HLF cells transform through 
the induced expression of Bcl2 while MLL-fusion cells are more dependent on Mcl1 (48) 
(43).
Our data suggests a strong link between Mcl1 expression, mediated by Shp2, and increased 
LSC frequency. Among the anti-apoptotic family of proteins, Mcl1 is indispensible for the 
self-renewal of normal hematopoietic stem cells (57). These data may suggest similar 
mechanisms governing the self-renewal of both normal hematopoietic stem cells and 
leukemic stem cells that may reflect an obstacle to therapeutic targeting. Indeed, 
upregulation of Mcl1 and Bcl-xL by Shp2 was reported in normal hematopoietic stem cells 
and regulation of Bcl-xL by Shp2 was reported in FLT3-ITD positive leukemic cells (24, 
27). Further, differential regulation of Bcl-xL was reported by Shp2 in human leukemic 
HL60 cells compared to MV4;11 cells (27). Thus, Shp2 may differentially regulate anti-
apoptotic genes dependent on the leukemic subtype. Further studies characterizing anti-
apoptotic gene expression in various leukemic subtypes will be required to better understand 
this regulation.
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Figure 1. 
Shp2E76K increases leukemia colony formation by MLL-AF9 in vitro. (A) Hematopoietic 
progenitor cells were transduced with empty MSCV, MIEG3 or MSCV-F-MLL-AF9 
(MA9), MSCV-E2A-HLF (EH) and MIEG3-Shp2E76K (E76K) and plated in 
methylcellulose media for three rounds of 7 day culture. Data shows the average and 
standard deviation from three independent experiments with duplicated samples normalized 
to the highest colony formation. Data indicates cooperation between Shp2E76K and MLL-
AF9 but not E2A-HLF. (* p<0.05; t-test) (B) Representative colonies after the second round 
of the methylcellulose colony assays were pictured using a 2x lens on an Olympus IX71 
microscope (Camera: DP73; objective lens: Plan N 2x/0.06; software: cellSens Entry 1.7)
(scale bar = 500μm). Images illustrate increased colony formation specifically in MLL-AF9 
transduced cells with Shp2E76K. Cell morphology is obtained by staining cytospun cells 
following the second round of the colony assay. Cells are imaged using a 100x lens on an 
Olympus BX41 microscope (Camera: DP71; objective lens: 100x/1.30; software: DP 
Controller)(scale bars = 50μm). (C) Overexpression of Ptpn11 is confirmed from the colony 
assay described in (A) by real-time qPCR following RNA extraction from cells collected 
after the first round of the colony assay. Expression is shown relative to β-actin expression.
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Figure 2. 
Shp2E76K accelerates leukemia development by MLL-AF9 in vivo. (A) Survival of mice 
transplanted with cells transduced with MSCV+MIEG3 (n=4), MSCV+E76K (n=4), 
MA9+MIEG3 (n=11, median survival = 125 days), MA9+E76K (n=11, median survival = 
60 days). MA9+E76K accelerates leukemogenesis compared to MA9+MIEG3 (p=0.0004, 
Log-Rank) (B) Splenomegaly is observed in leukemic mice injected with MA9+MIEG3 or 
MA9+E76K. Spleen weights for diseased mice are shown in the panel on the right. (C) 
Spleen, liver and bone marrow samples were collected from diseased MA9+MIEG3 and 
MA9+E76K mice and censored MSCV+MIEG3 and MSCV+E76K mice. Tissue sections or 
cytospun bone marrow was stained by H&E and imaged with an Olympus BX41 microscope 
(Camera: DP71; objective lens: 10x/0.3 for spleen, 100x/1.30 for liver and bone marrow; 
software: DP Controller) (scale bar = 500μm for the spleen and 50μm for liver and bone 
marrow images). Infiltrating leukemic blasts are evident in MA9 and MA9+E76K mice. (D) 
Top: Expression of Shp2 in mouse splenocytes was detected by western blot. Samples are 
numbered in chronological order of detection of disease. Bottom: β-Actin normalized Shp2 
protein expression is plotted relative to disease latency. (E) Expression of Ptpn11, Hoxa9 
and Meis1 detected by real-time PCR. (* p< 0.05; t-test) (F) Mean fluorescence intensity 
(MFI) of Sca1, c-Kit, Cd11b and Gr1 on MA9+MIEG3 and MA9+E76K splenocytes 
detected by flow cytometry. (* p< 0.05; t-test). In (B), (E) and (F), median value and error 
bar stands for interquartile range are shown with each dot representing one mouse. (G) 
MA9+MIEG3, MA9+E76K stem cell frequency determined by serially diluted secondary 
transplantation. 5 cells (n=10), 20 cells (n=5), 50 cells (n=10), 200 cells (n=10) and 1000 
cells (n=5) from diseased primary mice were injected by i.v. into sublethally irradiated 
C57bl/6 syngeneic recipients. Figures and stem cell frequency were generated by ELDA 
(46).
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Figure 3. 
Shp2E76K induces cytokine hypersensitivity in MLL-AF9 leukemic cells. (A) Lin-c-kit+ 
bone marrow cells were transduced with the indicated retroviruses and selected. Cells were 
grown in liquid culture and counted every other day. The total number of cells is plotted. (B) 
Shp2 expression in MA9+MIEG3, MA9+E76K cell lines are detected by western blot 
following whole cell lysis. (C) MA9+MIEG3 and MA9+E76K cells were cultured in serially 
diluted IL3 for 3 days. The growth rate was calculated and plotted showing cytokine 
hypersensitivity by MA9+E76K cells. (* p<0.0001; 2-way Anova; biological duplicates). 
(D) Western blotting was performed for total Erk and p-Erk in MA9+MIEG3 and 
MA9+E76K cells. Cells were cultured in serum free OPTI-MEM media overnight before a 
pulse with different doses of IL3 for 10 minutes.
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Figure 4. 
Shp2E76K up-regulates anti-apoptotic genes in MLL-AF9 cells. (A) Cells were cultured 
with 0.001ng/ml IL3 and Bcl2, Bcl-xL, and Mcl1 expression is shown for MA9+MIEG3 and 
MA9+E76K cells relative to Actin (* for Bcl2 p=0.066, for Bcl-xL p=0.0241, for Mcl1 
p=0.0067). Average transcript expression and standard deviation from biological duplicate 
experiments is shown relative to β–actin. (B) MA9+MIEG3 and MA9+E76K cells were 
cultured with 10ng/ml IL3 and Mcl1 expression was detected by western blotting.
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Figure 5. 
Mcl1 partially phenocopies Shp2E76K in MLL-AF9 cells. (A) Hematopoietic progenitor 
cells were transduced with empty vectors, Mcl1 alone, MA9 alone or MA9+Mcl1 and plated 
in methylcellulose. Colonies were counted after 7 days and replated for a total of three 
rounds. Colonies numbers are shown relative to the highest number of colonies observed. 
Error bars indicate standard deviation of biological duplicate experiments. (* p<0.05; t-test). 
Plates were stained with INT and imaged with a ChemiDoc XRS+ Imaging System after the 
3rd round. Data represents average of 3 independent experiments. (B) MA9+MSCVpuro and 
MA9+Mcl1 cells were cultured in serially diluted doses of IL3. Cells were counted after 
three days and growth rates are plotted. Data shows cytokine hypersensitivity with the 
overexpression of Mcl1. (* p<0.0001; 2-way Anova; biological duplicates). (C) Limiting 
dilution colony formation assays were performed with MA9+MIEG3 and MA9+E76K cells. 
The average number of colonies from biological duplicate experiments after 7 days in 
culture is plotted against seeding cell number with the dashed line representing a 95% 
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confidence interval. CFU potential is determined by 1/slope. (D) Mcl1 overexpression was 
detected by western blotting.
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Figure 6. 
Shp2E76K desensitizes MLL-AF9 cells to Mcl1 inhibition. (A) Growth rate of E2A-HLF, 
MA9+MIEG3, MA9+E76K, MA9+Mcl1 cells was determined after treatment with DMSO 
carrier or ABT-263, UMI-205, UMI-212 chemical inhibitors. Average growth rates from 
biological duplicate experiments are normalized to DMSO control and shown with standard 
deviation after 48 hours of chemical treatment and plotted against concentration with a fitted 
sigmoidal curve. Data indicates ABT-263 preferentially inhibits E2A-HLF while UMI-212 
mediated Mcl1 inhibition preferentially inhibits MLL-AF9 cell growth, which is mitigated 
by Shp2E76K. (2-away Anova, * p<0.05, **p<0.01, ****p<0.0001) (B) Quantified flow 
cytometry data from cells co-stained with AnnexinV and DAPI. Data shows increased 
apoptosis with chemical inhibition of Mcl1 or Bcl2/Bcl-xL which is lessoned by Shp2E76K. 
Statistical analysis was performed by 2-way Anova (** p<0.01, *** p<0.001; **** 
p<0.0001, ns= Not Significant) (C) MA9+MIEG3, MA9+E76K cells were transduced with 
shRNA retroviruses targeting Mcl1 and selected with Hygromycin for 1 week before 
performing a competitive growth assay in the presence of Doxycycline to induce shRNA 
expression. Average dsRed+ population percentages with standard deviation were 
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determined by flow cytometry after 1 day. Data is plotted relative to cells transduced with 
control shRNA targeting renilla (Ren sh). (D) Mcl1 knockdown was verified by western blot 
and the relative protein level was quantified with image lab software (BioRad).
Chen et al. Page 22
Leukemia. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 7. 
Human leukemia cell lines with activated SHP2 mutations show resistance to Mcl1 
inhibitors. (A) The growth rate of K562, U937, THP-1, Monomac6 and ML2 cells was 
determined following culture with UMI-205 (negative control), ABT-263 (Bcl-2/Bcl-xL 
inhibitor), and UMI-212 (Mcl1 inhibitor) and plotted against concentration with a fitted 
sigmoidal curve. Averaged data with standard deviation are shown for biological duplicate 
experiments normalized to DMSO treatment indicates the Shp2 mutation in U937 cells leads 
to greater resistance to Mcl1 inhibition. * indicates statistical significance (p<0.05) between 
the indicated cell line and the U937 cell line (2-way ANOVA) (B) Model of mechanistic 
cooperation between MLL-AF9 and Shp2E76K. A pre-leukemic clone containing an MLL-
AF9 fusion protein displays blocked differentiation and increased self-renewal through 
upregulation of Hoxa9 and Meis1. A second genetic lesion involving a gain of function 
(GOF) mutation to PTPN11 leads to increased expression of Mcl1 which increases leukemic 
stem cell (green) frequency and cell survival.
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